Q4 2022 Earnings Estimate for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Issued By Wedbush

Neurocrine Biosciences, Inc. (NASDAQ:NBIXGet Rating) – Wedbush boosted their Q4 2022 earnings per share (EPS) estimates for Neurocrine Biosciences in a research note issued on Thursday, April 28th. Wedbush analyst L. Chico now forecasts that the company will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.50. Wedbush currently has a “Outperform” rating on the stock. Wedbush also issued estimates for Neurocrine Biosciences’ Q1 2023 earnings at $0.51 EPS, Q2 2023 earnings at $0.74 EPS, Q3 2023 earnings at $0.93 EPS and Q4 2023 earnings at $1.12 EPS.

Neurocrine Biosciences (NASDAQ:NBIXGet Rating) last posted its quarterly earnings data on Friday, February 11th. The company reported ($0.08) EPS for the quarter, missing the Zacks’ consensus estimate of $0.61 by ($0.69). Neurocrine Biosciences had a return on equity of 6.89% and a net margin of 7.90%. The business had revenue of $312.00 million for the quarter, compared to analyst estimates of $317.72 million. During the same quarter in the prior year, the company earned $3.58 earnings per share. The company’s quarterly revenue was up 25.9% on a year-over-year basis.

Other research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of Neurocrine Biosciences in a report on Monday, February 14th. Barclays boosted their target price on shares of Neurocrine Biosciences from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Raymond James reiterated a “buy” rating and set a $125.00 price target on shares of Neurocrine Biosciences in a report on Friday, February 11th. Morgan Stanley lifted their price target on shares of Neurocrine Biosciences from $95.00 to $100.00 and gave the stock an “equal weight” rating in a report on Monday, February 14th. Finally, StockNews.com upgraded shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Monday, March 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Hold” and an average price target of $111.17.

Shares of NASDAQ:NBIX opened at $91.68 on Friday. The company has a 50-day simple moving average of $93.16 and a 200 day simple moving average of $88.81. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.83 and a current ratio of 3.96. The company has a market capitalization of $8.76 billion, a P/E ratio of 100.75, a price-to-earnings-growth ratio of 4.48 and a beta of 0.71. Neurocrine Biosciences has a 52-week low of $71.88 and a 52-week high of $108.01.

In other Neurocrine Biosciences news, Director Gary A. Lyons sold 15,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, April 25th. The shares were sold at an average price of $92.76, for a total value of $1,391,400.00. Following the completion of the transaction, the director now directly owns 208,697 shares of the company’s stock, valued at $19,358,733.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Matt Abernethy sold 3,310 shares of Neurocrine Biosciences stock in a transaction dated Monday, February 7th. The stock was sold at an average price of $80.79, for a total transaction of $267,414.90. The disclosure for this sale can be found here. Over the last three months, insiders have sold 46,743 shares of company stock valued at $4,232,771. 4.30% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of NBIX. Whittier Trust Co. raised its holdings in Neurocrine Biosciences by 102.8% in the fourth quarter. Whittier Trust Co. now owns 290 shares of the company’s stock worth $25,000 after buying an additional 147 shares during the last quarter. Moors & Cabot Inc. purchased a new position in Neurocrine Biosciences in the third quarter worth about $30,000. KB Financial Partners LLC purchased a new position in Neurocrine Biosciences in the fourth quarter worth about $33,000. Orion Capital Management LLC bought a new stake in shares of Neurocrine Biosciences in the fourth quarter worth approximately $34,000. Finally, CI Investments Inc. bought a new stake in shares of Neurocrine Biosciences in the third quarter worth approximately $39,000. 95.93% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Further Reading

Earnings History and Estimates for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.